야동동영상 INGELHEIM, GERMANY--( / )--Boehringer Ingelheim announced today that Cowtribe is the first recipient of investment and non-financial support from the Boehringer Ingelheim Social Engagement (BI SE) initiative, a program which aims to close a critical financing gap for social businesses in vulnerable communities.
Cowtribe, a leading last-mile veterinary delivery company from Ghana, leverages technology to help coordinate deliveries of veterinary vaccines and other animal health products to rural and underserved communities, where many farmers are dependent on just a few animals.
With innovative solutions, such as software supported demand & supply matching, as well as a partnership for drone delivery, Cowtribe bridges the final, critical last mile to get animal medication and veterinary vaccines to smallholder farmers in remote areas. The social start-up, which was founded in 2017, plans to expand to other African markets and collaborates with the government of Ghana on a national livestock identification system, based on Cowtribe’s market data and network.
Start-ups often need more than just funding. BI SE was launched in 2021 to provide investment and non-financial support, together with complementary partners and by engaging Boehringer Ingelheim’s employees to help scale up solutions of social businesses to create systemic change.
BI SE underlines Boehringer Ingelheim’s commitment to find innovative financing solutions with the intention to scale social impact. It complements Boehringer Ingelheim’s flagship initiative, Making More Health, which has committed to positively impact the lives and health of 50 million people through supporting social entrepreneurs in vulnerable communities.
“We are delighted to grant the first investment of Boehringer Ingelheim Social Engagements to Cowtribe,” said Ilka Wicke, Global Head of Making More Health at Boehringer Ingelheim. “Every year smallholder farmers lose about 25 percent of their livestock, due to preventable diseases. Cowtribe is at the forefront of addressing this problem by transforming the critical last-mile distribution in Africa. Their smart logistics platform, based on demand optimization, combined with innovative drone delivery concepts, helps secure the availability and accessibility of vaccines for smallholder farmers. Together, we can significantly improve the lives of many farmers across Africa.”
“In Africa, there are over 200 million smallholder farmers without access to reliable animal health services. We are incredibly excited to partner with BI SE to support our mission to make access to animal vaccines in Africa a right, not a privilege,” added Peter Awin, co-founder and CEO of Cowtribe. “This funding will be used to accelerate our growth in Ghana. This will involve entering new communities and building robust tech capabilities, product development, and attracting new talent.”
Financial details will not be disclosed. The news was announced during the “Making More Health Together 2022" convention, a two-day hybrid event, which focuses on the empowerment of social entrepreneurship and topics relevant to human and animal health, as well as social innovation.
Click here for the full release:
View source version on businesswire.com:Korea Newswire distributes your news across every media channels through the industry’s largest press release distribution network
NEWCASTLE, 123탑 섹시동영상 ENGLAND--( / )--Iksuda Therapeutics (Iksuda), the developer of enhanced, new-generation of Antibody Drug Conjugates (ADCs), today announces it has executed its option to secure exclusive, worldwide 123탑 박민영이민호 rights to develop a novel class of tumour-activated prodrug payloads from the University of Goettingen, following a successful collaboration exemplifying the series in ADC formats. The highly potent and selective payload series represents a powerful new class within ADC development with novel protein alkylating cytotoxicity. Iksuda will drive onward development and commercialisation, incorporating the tuneable payload series in its ADC pipeline and payload armoury, to create best in class ADC therapeutics for nominated targets associated with haematological and solid 신교동포커 10대속옷쇼핑몰 tumours with high unmet need.
The partnership with the University of Goettingen was founded on Iksuda’s commitment to expand its payload armoury and optimise ADC design according to 노노카하나 Theantigen. The programme confirmed the value of tumour-selective activation of these powerful cytotoxic agents, conjugated with Iksuda’s stable conjugation technology (PermaLink®), in widening the therapeutic index of ADCs. The novel protein-alkylating mode-of-action of the payload series differs from the field’s primary focus 123탑 베카 of intra- or DNA inter-strand cross-linking, conferring benefits against drug resistance mechanisms. Through the combination of PermaLink technology and the protein alkylating prodrugs, the Company aims to enable the differentiated development of 123탑 스타화보닷컴 more powerful ADCs with improved tumour killing, aligned with improved safety index and an ability to overcome potential 123탑 오인혜 tumour resistance.
Iksuda has demonstrated the potential value of prodrug approaches 자브FREE Iksudatargeted cancer therapeutics through 123탑 박은지방송사고 its recent license of a CD19-targeting ADC from LegoChem Biosciences (“LCB”) for hard-to-treat B-cell cancers, 123탑 엄빠주의반전만화 including diffuse large B-cell lymphoma and Burkitt lymphoma. The ADC contains LCB’s prodrug DNA-cross-linking payload, with preclinical 123탑 엄빠사이트 data confirming an impressive increase in therapeutic index over comparators. Under a broader agreement, the Company has gained access to LCB’s prodrug payload platform for use in nominated Iksuda targets.
Dr Dave Simpson, PhD, Chief Executive Officer, Iksuda Therapeutics, said: “Iksuda’s successful partnership with the University of Goettingen, led by Professor Lutz Tietze, and subsequent licensing agreement demonstrates our continued work in building and refining approaches to ADC 123탑 라이브69TV development. We are successfully responding to the industry-wide challenge of being able to treat all patients with cancer. Iksuda remains focussed 신교동포커 섹 on building a pipeline of next-generation ADCs with improved therapeutic index through 123탑 페티쉬코리아 our internal and external pipeline, harnessing our deep understanding in the field and accepting the challenge of targeting areas of high unmet 123탑 소원을말해봐태연바탕화면 clinical need.”
Dr Jens-Peter Horst, PhD, 프리바디 DrExecutive Officer, MBM ScienceBridge, the technology transfer organisation of the University 123탑 of Goettingen, said: “This agreement is exemplary for the successful transfer of many years of academic research and development work into a very promising and innovative cancer therapy.”
View source version on businesswire.com:Korea Newswire distributes your 123탑 섹시한사진 news across every 신교동포커 명단공개의외로글래머 xxxsex Viewchannels through the industry’s largest 123탑 서현반전몸매 press release distribution network
폰,xxxsex,xxxsex,스테키,꿀넷,러브섹스,러브섹스,우리카지노주소,하모닉젤동영상,여성세정제,오피다방,바로보고,망포동성인게임장,rcwOwqpf
